FDA approves Hengrui Medicine's PARP inhibitor international multi-center Phase 3 clinical trial for prostate cancer
Time of Update: 2021-03-24
Source: Guanlan PharmaceuticalRecently, Hengrui Medicine announced that its PARP inhibitor fluzoparib capsules have been approved by the US FDA to conduct an international multi-center phase 3 clinical trial to evaluate fluzoparib capsules combined with abiraterone acetate tablets and prednisone tablets.
, randomized, controlled, multi-center clinical research papers published in the international journal "Plant Medicine"
Time of Update: 2020-05-30
The study was conducted in more than 20 hospitals across the country to treat new coronary pneumonia, and it was not possible to conduct double blindness, taking into account the urgency of epidemic prevention and control; According to the study plan
LabTech China Congress, 2019 China International laboratory planning, construction and management
Time of Update: 2019-09-06
Modern laboratory has already become a space complex with the characteristics of scientific research, work, innovation, compliance, comfort, safety, energy conservation
progress has been made in the international evaluation of innovative traditional Chinese medicine
Time of Update: 2018-12-24
On December 19, Gansu Province issued a notice that Yangzi River actively applied for price selection in the implementation of "4 + 7 urban drug centralized procurement" in Gansu Province and added another specification of hanging net.
These clinical research results of traditional Chinese medicine have been published in the top international journals
Time of Update: 2015-11-16
After its evidence-based medicine research was published in the top international journals, the annual sales of musk Baoxin Pill last year has exceeded 1 billion, becoming a veritable large variety.
The second international clinical research progress of traditional Chinese medicine and health care academic conference opened in Guizhou in August
Time of Update: 2015-05-22
Traditional Chinese medicine, rooted in Chinese culture, is an important health, economic, scientific and technological, cultural and ecological resource, as well as a unique
Shenzhen Huace testing and University of California cooperate to establish clinical medicine laboratory
Time of Update: 2014-04-10
Source: on April 10, 2014, the board of directors of Regent of University of California system officially approved UCLA health to establish a joint venture with Shenzhen CTI